Related Experiment Video
Updated: Aug 7, 2026
Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Transmyocardial laser revascularization as an adjunct to coronary artery bypass grafting
1Department of Cardiothoracic Surgery, Heart Center of Indiana, Indianapolis, Indiana 46290, USA. kallen2340@aol.com
Insights
Transmyocardial revascularization (TMR) improves outcomes for patients with incomplete revascularization after coronary artery bypass grafting (CABG). Adjunctive TMR is recommended for this high-risk group, enhancing treatment for refractory angina.
Area of Science:
- Cardiovascular Surgery
- Interventional Cardiology
Background:
- Coronary artery disease (CAD) affects many patients, often managed with medical therapy or revascularization.
- Complete revascularization is crucial, as up to 25% of patients undergoing coronary artery bypass grafting (CABG) experience incomplete revascularization.
- Incomplete revascularization after CABG is a significant predictor of mortality and adverse cardiovascular events.
Purpose of the Study:
- To evaluate the efficacy of Transmyocardial Revascularization (TMR) as an adjunctive therapy for patients with incomplete revascularization post-CABG.
- To assess the impact of TMR on clinical outcomes in patients with debilitating angina not amenable to conventional revascularization.
Main Methods:
- Review of randomized controlled trials with long-term follow-up and clinical experience data.
- Analysis of outcomes in patients receiving TMR adjunctively to CABG compared to those treated conventionally.
- Focus on patient groups with incomplete revascularization after initial CABG.
Main Results:
- Adjunctive TMR in patients with incomplete revascularization after CABG demonstrated significantly improved clinical outcomes.
- Long-term follow-up confirmed the benefits of TMR in this challenging patient population.
- TMR provides a viable surgical option for refractory angina in specific CAD patient subsets.
Conclusions:
- Transmyocardial revascularization (TMR) is a recommended adjunctive therapy for patients with incomplete revascularization following CABG.
- The Society of Thoracic Surgeons guidelines support the use of TMR for this difficult-to-treat group.
- TMR offers significant clinical benefits, improving outcomes for patients with debilitating angina unresponsive to conventional treatments.
Abstract:
Many patients with angina related to coronary artery disease respond to medical management or can be completely revascularized using available percutaneous coronary interventions or coronary artery bypass grafting (CABG). There is evidence, however, to indicate that up to 25% of patients are incompletely revascularized following CABG and that incomplete revascularization is a significant independent predictor of early and late mortality and adverse events. Transmyocardial revascularization (TMR) is a surgical option for patients with debilitating angina due to coronary artery disease in areas of the heart not amenable to complete revascularization using conventional treatments. In randomized, 1-year controlled trials with long-term follow-up and in additional clinical experience, TMR performed adjunctively to CABG in patients who would be incompletely revascularized by CABG alone has yielded significantly improved clinical outcomes. Based on these published results, the Society of Thoracic Surgeons has issued a practice guideline recommending adjunctive TMR in this difficult patient group.
